Crossref

1. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study

- Matthew Anson

- Sizheng S. Zhao

- Philip Austin

- Gema H. Ibarburu

- Rayaz A. Malik

- Uazman Alam

2. Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report

- Woohyuk Yoon

- Joon Ho Lee

3. Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients

- Sanghwa Park

- Jiseon Jeong

- Yunna Woo

- Yeo Jin Choi

- Sooyoung Shin

4. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination

- Johan H Jendle

- Francisco J Ampudia-Blasco

- Martin Füchtenbusch

- Paolo Pozzilli

5. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

- Karn Wijarnpreecha

- Elizabeth S. Aby

- Aijaz Ahmed

- Donghee Kim

6. Early Use of SGLT2 Inhibitors in Heart Failure With Preserved Ejection Fraction: Quantitative Analysis of Cardiac Biomarkers, Renal Function, and In-Hospital Mortality

- Luiz Francisco de Souza Neto

- Camila Maria Bertão Carvalho

- Laura Emilly de Moura Bezerra

- Luciano Victor Vasconcelos Saldanha

- Artur Freire Brito

- Kerolaine Silva Fonseca

- Fernando Paniago Santini

- Dionéa Ferreira Ayres Viana

- Hildo Santiago Reis de Aguiar

- Amanda Pinheiro Oliveira

- Mariana Mota Benevides de Oliveira

- Nelso Gabriel Lippo Turmina

- Luis Guilherme Rodrigues de Almeida Moutinho

- Rebeca Carvalho Wanderley de Lima Lôbo

- Layanna Pessoa Marçal de Oliveira

- Raíssa Maria Silvestre Santos

- Aurélia Lorena Toscano de Medeiros Borges de Méllo

- Levy Alves Pinto Loureiro

- Dulce Cerqueira Ferreira Cavalcanti

- Ana Clara Onofre Brito Chaves

- José Mateus da Silva Bomfim

- Ellen Pereira Areal

- Maria Eduarda Morales Rodrigues

- Rodrigo Porcionato

- Joseane Oliveira Braga Nascimento

- Harley Davidson Rocha de Lima

- Giovana Mendelski Pereira

7. The Evaluation of Cardiovascular Risk in Diabetic Patients

- S. Kosirova

- D. Rubintova

- J. Lacka

- J. Klimas

- T. Foltanova

- I. Tumova

8. Metabolic effects of empagliflozine

- Antonina Kedyk

- Oleksandr Kutsyn

9. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination

- Johan H Jendle

- Francisco J Ampudia-Blasco

- Martin Füchtenbusch

- Paolo Pozzilli

10. SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM

- Birdie Huang

- Chieh-Li Yen

- Chao-Yi Wu

- Chung-Ying Tsai

- Jia-Jin Chen

- Ching-Chung Hsiao

- Yung-Chang Chen

- I-Chang Hsieh

- Huang-Yu Yang

11. A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population

- Lianglan Shen

- Hongli Yang

- Xingxing Fang

- Huaxing Huang

- Wubin Yao

- Dongmei Chen

- Yan Shen

12. A practical review of diabetes mellitus type 2 treatment in primary care

- Justin T. Call

- Pedro Cortés

- Dana M. Harris

13. Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy

- Mouhamed Nashawi

- Mahmoud S Ahmed

- Toka Amin

- Mujahed Abualfoul

- Robert Chilton

14. Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus

- Haoyi Yang

- Yuwen Zhang

- Yuxin Hong

- Yuan Wei

- Yuning Zhu

- Lei Huang

- Yuanxun Yang

- Runbin Sun

- Juan Li